Long-term immune reconstitution and T cell repertoire analysis after autologous hematopoietic stem cell transplantation in systemic sclerosis patients

Table 1 Patients’ clinical characteristics (n = 10) with diffuse cutaneous systemic sclerosis (SSc) before autologous hematopoietic stem cell transplantation (aHSCT) and graft characteristics at study inclusion^a

	Group A patients (n = 5)						Group B patients (n = 5)
	1	2	3	4	5	Mean (±SD)	1	2	3	4	5	Mean (±SD)	Mean (±SD)
Patients characteristics at inclusion
Age, years	40	56	53	47	24	44 ± 12.7	24	27	52	19	32	30.8 ± 12.7	37.4 ± 13.9
Sex	M	M	M	F	F	–	M	M	F	F	F	–	–
Disease duration, months^b	6	18	29	20	18	18.2 ± 8.2	3	6	27	24	36	19.2 ± 14.1	18.7 ± 10.9
Steroids at inclusion, mg/day	7	10	0	10	0	5.4 ± 5.1	0	7	0	0	0	1.7 ± 3.5	3.8 ± 4.6
SHAQ (0–3)	–	0.87	2.87	1.625	2	1.8 ± 0.8	1.25	2	–	2.125	0.16	1.4 ± 0.9	1.6 ± 0.8
mRSS (0–51)	26	22	37	29	25	27.8 ± 5.7	16	22	52	42	23	31 ± 15.2	29.4 ± 11.0
FVC, %	56	89	87	108	58	79.6 ± 22.2	52	72	63	56	–	60.7 ± 8.8	71.2 ± 19.3
DL_CO, % predicted	45	75	72	56	48	59.2 ± 13.7	56	47	72	46	30	50.2 ± 15.4	54.7 ± 14.5
LVEF, %	58	82	62	61	73	67.2 ± 10.0	60	63	–	67	70	65 ± 4.4	66.2 ± 7.7
Serum creatinine, μmol/L	67	76	77	–	51	67.8 ± 12.0	52	73	60	59	71	63 ± 8.8	65.1 ± 10.0
CRP level, mg/L	62	2	15	20	2	20.2 ± 24.7	9	51	66	13	10	35 ± 27.8	26.8 ± 25.6
Anti-Scl-70 antibodies, U/ml	120	+	0	10.2	+	43.3 ± 66.5	0	+	39.1	130	21.3	47.6 ± 57.2	45.8 ± 55.8
Graft characteristics and engraftment duration
CD34+ cells × 10⁶ infused/kg^c	4.9	2.9	4.9	2.5	5.3	4.1 ± 1.3	5.8	6.3	5.19	8.79	7.2	6.9 ± 2.0	5.5 ± 2.2
CFU-GM cells × 10⁴ infused/kg^d	12.37	2.7	–	–	88	34.3 ± 46.7	23	48	9.97	52.56	91	44.9 ± 31.2	40.9 ± 34.7
Days to 0.5 × 10⁹ neutrophils/L	10	10	11	10	10	10.2 ± 0.4	10	7	10	9	9	9 ± 1.2	9.6 ± 1.1
Days to 20 × 10⁹ platelets/L	8	10	10	9	7	8.8 ± 1.3	8	7	10	12	6	8.6 ± 2.4	8.7 ± 1.8
Days to 50 × 10⁹ platelets/L	10	10	13	9	10	10.4 ± 1.5	9	7	Not reached	14	9	9.7 ± 3.0	10.1 ± 2.1

Anti Scl-70 (antitopoisomerase I) antibodies were measured by ELISA and quantified results expressed in arbitrary units (U/ml)
M male, F female, SHAQ Scleroderma Health Assessment Questionnaire, STE steroids, mRSS modified Rodnan skin thickness score, FVC forced vital capacity, DL _CO diffusing capacity for carbon monoxide, LVEF left ventricular ejection fraction, MUGA multiple gated acquisition scan, CRP C-reactive protein. + positive for anti-Scl-70 antibodies
^aSee the “Results” section for description of groups
^bCalculated since first diagnosis of systemic sclerosis
^cQuantity of CD34+ progenitor cells contained in the graft. CD34+ cell recovery after cryopreservation was 95% (range 75–100%)
^dGM-CFUs/kg were counted on day 14 using a clonogenic progenitor assay as previously described[8]

ISSN: 1756-8722